23 articles for thisTarget

---

The following articles (labelled with PubMed ID or TBD) are for your review

PMID	Data	Article Title	Organization
27994728	23	Pyrazole Inhibitors of GluN2B NMDA Receptor Subunit.	Dart Neuroscience
27061977	8	Benzimidazolone bioisosteres of potent GluN2B selective NMDA receptor antagonists.	Institut F£R Pharmazeutische Und Medizinische Chemie Der Universit£T M£Nster
25458498	29	Synthesis, GluN2B affinity and selectivity of benzo[7]annulen-7-amines.	Institut F£R Pharmazeutische Und Medizinische Chemie Der Universit£T M£Nster
12639560	34	Novel N1-(benzyl)cinnamamidine derived NR2B subtype-selective NMDA receptor antagonists.	Merck Sharp & Dohme Research Laboratories
22366657	39	A novel series of benzimidazole NR2B-selective NMDA receptor antagonists.	Glaxosmithkline
18434149	23	Reactive derivatives for affinity labeling in the ifenprodil site of NMDA receptors.	University Of Strasburg
11909726	36	5-Phosphonomethylquinoxalinediones as competitive NMDA receptor antagonists with a preference for the human 1A/2A, rather than 1A/2B receptor composition.	Novartis Pharma
21524576	69	2,6-Disubstituted pyrazines and related analogs as NR2B site antagonists of the NMDA receptor with anti-depressant activity.	Astrazeneca Pharmaceuticals
20965739	66	Conformationally constrained NR2B selective NMDA receptor antagonists derived from ifenprodil: Synthesis and biological evaluation of tetrahydro-3-benzazepine-1,7-diols.	Institut FüR Pharmazeutische Und Medizinische Chemie Der WestfäLischen Wilhelms-UniversitäT MüNster
20875744	6	Synthesis and biological evaluation of radio-iodinated benzimidazoles as SPECT imaging agents for NR2B subtype of NMDA receptor.	Hamamatsu University School Of Medicine
20361801	100	Bivalent beta-carbolines as potential multitarget anti-Alzheimer agents.	Friedrich-Schiller-Universitat Jena
19648007	3	Synthesis and evaluation of novel tricyclic benzo[4.5]cyclohepta[1.2]pyridine derivatives as NMDA/NR2B antagonists.	Merck Research Laboratories
17498948	24	Cyclic benzamidines as orally efficacious NR2B-selective NMDA receptor antagonists.	Merck Research Laboratories
17249648	64	Identification and characterization of 4-methylbenzyl 4-[(pyrimidin-2-ylamino)methyl]piperidine-1-carboxylate, an orally bioavailable, brain penetrant NR2B selective N-methyl-D-aspartate receptor antagonist.	Merck Research Laboratories
15225705	19	Oxamides as novel NR2B selective NMDA receptor antagonists.	Gedeon Richter
14552795	13	Indole-2-carboxamides as novel NR2B selective NMDA receptor antagonists.	Gedeon Richter
12639561	51	Orally efficacious NR2B-selective NMDA receptor antagonists.	Merck Research Laboratories
12519057	22	3-[(2-Methyl-1,3-thiazol-4-yl)ethynyl]-pyridine: a potent and highly selective metabotropic glutamate subtype 5 receptor antagonist with anxiolytic activity.	Merck Research Laboratories
10741546	66	Parallel synthesis of a series of subtype-selective NMDA receptor antagonists.	Parke-Davis Pharmaceutical Research
17761421	10	Identification of novel chemical inhibitors for ubiquitin C-terminal hydrolase-L3 by virtual screening.	Waseda University
15771420	58	Discovery of 1-(3'-aminobenzisoxazol-5'-yl)-3-trifluoromethyl-N-[2-fluoro-4-[(2'-dimethylaminomethyl)imidazol-1-yl]phenyl]-1H-pyrazole-5-carboxyamide hydrochloride (razaxaban), a highly potent, selective, and orally bioavailable factor Xa inhibitor.	Bristol-Myers Squibb Pharmaceutical Research Institute
11881999	123	Novel 4-anilinoquinazolines with C-7 basic side chains: design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors.	Astrazeneca